Startup Fundraising · 2026-06-29 · 8 min
Key moments - from our scoring
Substance score
53 / 100
Five dimensions, 20 points each
The seed round category has become so inflated that it no longer communicates meaningful information about company stage or capital requirement. Hang Ten Systems, founded by former Infosys CEO Vishal Sikka, raised $32 million labeled as seed - a valuation-management strategy enabled by founder pedigree and strategic investor participation from Aramco Ventures, which signals enterprise distribution access rather than pure financial return. By contrast, Engimmune Therapeutics represents the traditional seed model: a biotech spinout from ETH Zurich's Sai Reddy lab raising 15.5 million Swiss francs with a hard scientific deliverable (TCR-T therapies for solid tumors) co-led by Pureos Bioventures and Novo Holdings. Meanwhile, Canopy's $8.5 million round from Arrington Capital, Fenbushi Capital, Borderless Capital, and SNZ Capital exemplifies opacity - four crypto-native investors, no declared lead, no stated pricing mechanism, and buzzword-heavy positioning ('AI-assisted Web3 infrastructure'). The episode argues that 'seed' has become partly a tool to defer Series A scrutiny, with valuations now routinely hitting $80.5 million at the 95th percentile. For founder-led companies like Sikka's, the label matters less than burn rate against enterprise deliverables; for science-backed plays like Engimmune, the stage still reflects genuine early-stage risk; for Web3 infrastructure like Canopy, the lack of transparent lead signals syndicate appetite without conviction.
Aramco Ventures' participation signals where Vishal Sikka thinks his first big enterprise customers live and suggests interest in data access, supply-chain leverage, and hedging on energy transition - not just financial return.
Per Carta data cited in a Euclid Ventures analysis, 95th-percentile seed valuations hit $80.5 million in 2025, nearly three times where they were six years ago, with 42% of all seed rounds above $5 million.
Engimmune is a biotech spinout from ETH Zurich's Sai Reddy lab raising 15.5 million Swiss francs with a concrete scientific deliverable (TCR-T therapies for solid tumors), co-led by Pureos Bioventures and Novo Holdings, representing the traditional seed model priced on science rather than narrative.
Canopy's $8.5 million round from Arrington Capital, Fenbushi Capital, Borderless Capital, and SNZ Capital shows syndicate appetite but no obvious lead-level conviction, making the pricing mechanism and valuation opaque.
Hang Ten has already named Siemens Gamesa and Fresenius as customers, which is more than most seed decks can claim and shifts the evidence bar closer to proof before Series A investors evaluate the round.
Our reviewer’s read on each dimension, with quotes from the episode.
The episode packs several valuable operational insights about seed-stage fundraising mechanics: the semantic inflation of 'seed' rounds, how strategic checks signal customer intent, the capital requirements for AI infrastructure, and the behavioral signals from cap table structure. However, it mixes insight with recycled observations (e.g., 'AI needs more upfront capital') and some filler transitions ('Tap follow so the next episode finds you').
95th-percentile seed valuations hit $80.5 million last year - nearly three times where they were six years ago
Aramco's venture arm coming in points to where Sikka thinks his first big enterprise customers live
The core insight - that 'seed' has become a valuation-management fiction - is sharp and somewhat contrarian, but the supporting analysis relies heavily on cited TechCrunch and Per Carta data rather than original observation. The framing of strategic checks as distribution hedges is competent but not novel. The distinction between Engimmune's honest pricing vs. Canopy's opacity is useful but underdeveloped.
is 'seed' still a useful category, or is it a strategic fiction now?
Aramco Ventures makes it more than a pure financial bet; that check is buying enterprise distribution credibility before there's a product everyone can benchmark
This is a solo-host analytical piece with zero guest interviews. The episode references Vishal Sikka and Sai Reddy via news excerpts but does not interview them or any operators. No practitioners are actually present to validate or challenge claims made about their own rounds.
Vishal Sikka has raised $32 million (approximately ₹302 crore) in a seed funding round led by Mayfield Ventures
spun out of Sai Reddy's lab at ETH Zurich
Strong on named rounds, dollar figures, and verifiable data points (Thinking Machines Lab $2B seed, Unconventional AI $475M, Per Carta 95th-percentile $80.5M, TechCrunch March piece on $10M seeds). The episode names specific customers (Siemens Gamesa, Fresenius) and technology targets (TCR-T therapies for solid tumours). Weaknesses: no revenue metrics for named companies, no burn-rate data, and vague product descriptions for Canopy.
$32 million seed. Hang Ten Systems the enterprise AI startup run by former Infosys CEO Vishal Sikka
95th-percentile seed valuations hit $80.5 million last year - nearly three times where they were six years ago
This is monologue-driven analysis with no live conversation, so craft is evaluated on host questioning depth and intellectual rigor. The host asks thoughtful meta-questions ('Is seed still a useful category?', 'When does avoiding the A label become a liability?') but never pushes back on their own answers or explores counterarguments. No genuine disagreement or challenge. Some softball rhetorical moves ('I love it' on BaseLaunch) pad rather than sharpen.
When does avoiding the 'A' label start becoming a liability instead of an asset? That's the tradeoff.
I love it. Unsexy plumbing.
Computed from the transcript - who did the talking, and the words that came up most.
Hang Ten Systems raised a $32 million seed led by Mayfield, while Engimmune and Canopy added early-stage checks. The common thread: “seed” now spans enterprise AI talent, biotech translation and Web3 infrastructure buildouts. In this episode Hang Ten Systems Raises $32M Seed Round Led by Mayfield - Arab Founders Hang Ten Systems Raises $32M Seed Round Led by Mayfield
Transcribed and scored by The B2B Podcast Index.
A $32 million seed round. Somewhere a Series A is filing a missing-persons report. This is Startup Fundraising, Monday tape. Thin day after the mega-round week - which means we get to be precise instead of loud.
Hang Ten, Engimmune, Canopy. Same label on all three, three completely different stories. Let's start with Vishal Sikka's $32 million. Tap follow so the next episode finds you.
Here's Arab Founders: Hang Ten Systems the AI startup founded by former Infosys CEO Vishal Sikka has raised $32 million (approximately ₹302 crore) in a seed funding round led by Mayfield Ventures. The round also attracted participation from Aramco Ventures, the venture capital arm of Aramco, alongside several angel investors. A former Infosys CEO raising a $32 million seed. That's a category of one - Sikka's name is the asset here, more than the product.
Mayfield leads, and then there's the line worth pausing on - Aramco Ventures writing a strategic check. Adam, Aramco's venture arm coming in points to where Sikka thinks his first big enterprise customers live. Right, a state-linked oil major isn't parking a strategic check just for the return. They want data access, supply-chain leverage, maybe a hedge on their own transition.
So what has to go right for Sikka over the next two years so this round doesn't define his legacy the wrong way? He's already got Siemens Gamesa and Fresenius named as customers, which is more than most seed decks can claim. And after a week where Quantifind pulled $200 million and Trase launched on a $107 million seed, $32 million almost reads conservative. That's the inversion, isn't it?
$32 million is now the restrained option. Pedigree is underwriting this until the revenue shows up. When a company raises a $32 million 'seed' round - like Hang Ten Systems just did - what is that label even doing at this point? Is 'seed' still a useful category, or is it a strategic fiction now?
Honestly, the label still matters; it just doesn't mean what it used to. Hang Ten Systems the enterprise AI startup run by former Infosys CEO Vishal Sikka raised $32 million led by Mayfield with a strategic check from Aramco Ventures and they're calling that seed. And it's not some lonely outlier anymore. Per Carta's 2025 data cited in a Euclid Ventures analysis 95th-percentile seed valuations hit $80.
5 million last year - nearly three times where they were six years ago - and 42% of all seed rounds were above $5 million. Thinking Machines Lab raised a $2 billion seed. Unconventional AI did $475 million at the same stage. For AI and infrastructure companies you often need a credible team serious compute and enterprise-grade architecture before you've got a single revenue dollar to show a Series A investor.
So the capital needed just to form the company has jumped by an order of magnitude. TechCrunch had a piece in March saying it's now 'pretty typical' to see a $10 million seed at a $40-to-$45 million post-money valuation for an AI company which would have looked aggressive in 2024. And with Hang Ten Aramco Ventures makes it more than a pure financial bet; that check is buying enterprise distribution credibility before there's a product everyone can benchmark. So if 'seed' is partly a valuation-management tool - a way to stay off the Series A metrics treadmill a little longer - what's the actual cost?
When does avoiding the 'A' label start becoming a liability instead of an asset? That's the tradeoff. The evidence bar at Series A moves from potential to proof, as one GP put it, and staying in 'seed' territory buys runway on that clock. But for Sikka - former Infosys CEO, SAP board-level executive - investors have already priced in the credibility.
The label matters less than the burn rate against deliverables. After $32 million the next round gets benchmarked on outcomes no matter what anyone calls it so watch whether Hang Ten can show enterprise contracts converting at scale before then. The Biotech Times writes: Pureos Bioventures and Novo Holdings co-led the financing of Engimmune Therapeutics, a spin-off from the research group of Prof. Sai Reddy at the Department for Biosystems Science and Engineering (Basel) of the Swiss Federal Institute of Technology in Zurich.
Okay after the Hang Ten thirty-two-million-dollar 'seed' we just picked apart Engimmune raises fifteen-and-a-half million Swiss francs and somehow sounds like the grown-up in the room. Right. Co-led by Pureos Bioventures and Novo Holdings - an actual co-lead structure two firms sharing the term sheet - spun out of Sai Reddy's lab at ETH Zurich. And the money goes toward something you can name - TCR-T therapies and soluble TCRs aimed at solid tumours.
You can put that on a pipeline slide; it's not just a vibe. This is the honest end of the seed spectrum. Biologics still get priced on the science - Novo and Pureos are underwriting Reddy's lab and a hard target rather than a narrative. Incubated through BaseLaunch, a regional innovation agency.
Unsexy plumbing. I love it. BBX writes: AI assisted development of Web3 infrastructure layer Canopy has completed a seed round financing of $8.5 million with participation from Arrington Capital Fenbushi Capital Borderless Capital and SNZ Capital.
The funds will be used to support the launch of the mainnet expansion of the engineering team and development of native AI development tools. Canopy - $8.5 million seed, with Arrington Capital, Fenbushi Capital, Borderless Capital, and SNZ Capital. Four names on the cap table, and nobody tagged as lead.
Four checks, no lead, no terms. So who set the price? Nobody's saying. And it pairs oddly with the Engram opacity from earlier - one shop wouldn't share a benchmark and this one won't name who's actually steering the round.
Same instinct, different blank space. 'AI-assisted Web3 infrastructure layer' - that's three buzzwords holding hands. The money goes to mainnet launch, engineering, and AI dev tools. For $8.
5 million, I want to know which one is the actual product. At $8.5 million with four crypto-native funds and nobody claiming the lead the cap table says there was syndicate appetite but no obvious lead-level conviction. If you follow startup funding, you might also like SpaceX IPO Watch: SpaceX valuation, stock news, and investor analysis, daily.
Follow the numbers before the ticker exists, wherever you listen to podcasts. Links to every story from today's episode are in the show notes, so if something caught your ear, that's where to dig in. That's Startup Fundraising for today. This is a Lantern Podcast.
Other episodes covering the same guests and topics, from across The B2B Podcast Index.
Kling’s $3B Raise Keeps AI Funding in Overdrive - July 03, 202678 / 100AI Infrastructure Megarounds Keep Coming - July 02, 202671 / 100Nigeria’s Startup Fund Meets the AI and Space Capital Rush - July 01, 202698 / 100Sharon AI’s $1.6B check puts compute back at the center - June 30, 202675 / 100AI Mega-Rounds Push From Games to Risk Ops - June 28, 202669 / 100
